CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas-Reference-Cited by-同舟云学术

CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

Published:2021-12-23 Issue: Volume: Page:1-4
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Fitzgerald Kelly N.¹^ORCID,Quesada Andres E.²,von Keudell Gottfried¹,Raj Sandeep¹,Lewis Natasha E.²,Dogan Ahmet³,Salles Gilles¹,Palomba M. Lia¹^ORCID

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Funder

Janice Stanton Fund

NIH/NCI Cancer Center Support

MSK Lymphoma SPORE

Farmer Family Foundation

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1992622

Reference17 articles.

1. Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold

2. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

3. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

4. Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

5. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma;Clinical Cancer Research;2024-04-25

2. Pharmacology to Practice;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

3. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma;Blood Reviews;2024-01

4. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?;Hematological Oncology;2023-11-08

5. Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL;Frontiers in Immunology;2023-04-14